Study to evaluate the efficacy of Dhanyamla Dhara in Diabetic Neuropathy

A Randomised Open Labelled Controlled Clinical Study to evaluate the efficacy of Dhanyamla Dhara in Diabetic Neuropathy - NIL

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056952

Enrollment

Registered

2023-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G64- Other disorders of peripheral nervous system

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Metabolically stable diabetic subjects with symptomatic Diabetic Peripheral Neuropathy. 2.Subjects of all gender between the age group of 30-65 years. 3.Subjects fulfilling the diagnostic criteria. 4.Subjects whose HbA1C is between 6.5 to 10%.

Exclusion criteria

Exclusion criteria: 1.Subjects where HbA1C >10% and 2.Subjects suffering from Type-1 Diabetes or Gestational Diabetes. 3.Pregnant and lactating women. 4.Subjects suffering from infectious diseases and non-healing ulcer/ ulcers of foot. 5.Any systemic illness that can interfere with the course of treatment.

Design outcomes

Primary

Measure	Time frame
Assessment of the patients condition will be done based on 1.Changes in Michigan Neuropathy Screening Instrument (MNSI) Questionnaire score 2.Changes in Toronto Neuropathy Clinical Scale (TCNS) Score 3.Changes in Visual Analog Scale (VAS) Timepoint: Before intervention 0th day After intervention 7th day Follow up 14th day	—

Secondary

Measure	Time frame
1. Changes in FBS value 2. Changes in PPBS valueTimepoint: Before intervention 0th day After intervention 7th day Follow up 14th day	—

Countries

India

Contacts

Public ContactDr Prajwal Narayan

Sri Sri College of Ayurvedic Science and Research Hospital Bangalore

prajwalayurveda@gmail.com8951072206

Outcome results